Showing results (211-220 of 233) with videos related to

Sort By:
Pageof 24
Targeted Oncology|December 16, 2016
Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancerJean-Luc Van Laethem, Hanno Riess, Jacek Jassem, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 4, 2021
Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino studyAlessandra Raimondi, Salvatore Corallo, Sara Lonardi, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2021
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trialGerardo Rosati, Sara Lonardi, Fabio Galli, et al.
JAMA Oncology|July 4, 2019
Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical TrialFilippo Pietrantonio, Federica Morano, Salvatore Corallo, et al.
ESMO Open|July 19, 2018
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable <i>RAS</i> and <i>BRAF</i> wild-type metastatic colorectal cancerBeatrice Borelli, Roberto Moretto, Sara Lonardi, et al.
Targeted Oncology|March 28, 2018
Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss StudyMaria Di Bartolomeo, Monica Niger, Giuseppe Tirino, et al.
Therapeutic Advances in Medical Oncology|February 4, 2020
Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a <i>post hoc</i> analysis from the adjuvant TOSCA trialSandro Barni, Gerardo Rosati, Sara Lonardi, et al.
Tumori|June 12, 2020
Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-SMaria Di Bartolomeo, Alessandra Raimondi, Fabiola Cecchi, et al.
Therapeutic Advances in Medical Oncology|November 6, 2024
Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burdenLeonardo Provenzano, Yong Xiang Gwee, Veronica Conca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 8, 2022
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O<sup>6</sup>-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA TrialFederica Morano, Alessandra Raimondi, Filippo Pagani, et al.
Pageof 24